Menu

SEC Charges Theranos With Fraud

The company raised more than $700 million based on false claims to investors, according to the complaint.

Mar 14, 2018
Jim Daley

ISTOCK, BET_NOIRE

The Securities and Exchange Commission (SEC) charged diagnostics company Theranos, its founder and CEO Elizabeth Holmes, and its former president Ramesh Balwani with engaging in “an elaborate, years-long fraud” to raise more than $700 million from investors, according to statement released today (March 14).

The SEC accuses Theranos, Holmes, and Balwani of making “numerous false and misleading statements” to investors and media. It alleges that in addition to falsely asserting that its portable blood analyzer could perform comprehensive tests from single blood drops, the company presented results from other manufacturers’ analyzers as its own and made a number of untruthful claims about users and revenues. For example, Theranos stated that the US Department of Defense (DoD) used its products in Afghanistan, although the DoD never deployed the company’s products.

“Investors are entitled to nothing less than complete truth and candor from companies and their executives,” Steven Peikin, Co-Director of the SEC’s Enforcement Division, says in the press release. “The charges against Theranos, Holmes, and Balwani make clear that there is no exemption from the anti-fraud provisions of the federal securities laws simply because a company is non-public, development-stage, or the subject of exuberant media attention.”

See “Refunds Coming to Theranos’s Arizona Customers

This is not the first time the company has been in hot water for its business practices. In 2017, the Centers for Medicare and Medicaid Services sent a warning letter to the company regarding substandard conditions in one of its labs. Theranos agreed to pay $200,000 in civil penalties to the state of Arizona and $25,000 in legal fees, and to provide Arizona customers with more than $4.5 million in reimbursements for blood-testing services they had purchased through the firm.

As a result of the SEC charges, Holmes agreed to pay a $500,000 penalty. She will also be banned from serving as an officer or director of a public company for 10 years and will be required to return the shares that she obtained through the fraudulent activity. The SEC says it plans to sue Balwani.

See “Theranos in Criminal Probe

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.